Mereo BioPharma Group plc Stock price London S.E.

Equities

MPH

GB00BZ4G2K23

Biotechnology & Medical Research

Delayed London S.E. 5-day change 1st Jan Change
- GBX -.--% Intraday chart for Mereo BioPharma Group plc -10.17% -.--%
Sales 2024 * - Sales 2025 * - Capitalization 333M 420M
Net income 2024 * -37M -46.76M Net income 2025 * -43M -54.34M EV / Sales 2024 * -
Net cash position 2024 * 69.4M 87.71M Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-39.6 x
P/E ratio 2025 *
-43.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.94%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6% MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Trading Week Modestly Higher Monday MT
More news

Latest transcript on Mereo BioPharma Group plc

Managers TitleAgeSince
Founder 53 15-02-28
Founder 66 15-02-28
Founder 64 15-07-09
Members of the board TitleAgeSince
Chairman 69 19-04-22
Director/Board Member - 22-11-09
Director/Board Member 59 19-04-22
More insiders
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.376 GBP
Average target price
3.938 GBP
Spread / Average Target
+65.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Mereo BioPharma Group plc
  4. Stock Mereo BioPharma Group plc - London S.E.